3月20日,丹麦制药巨头诺和诺德执行副总裁兼首席科学官Marcus Schindler在Linkedin发布了关于诺和诺德的研发组织架构调整的消息。公告表示,本次重组涉及研究与早期开发(R&D)部门,包含三大治疗领域:1.糖尿病、肥胖和MASH;2.心血管和肾脏疾病;3.罕见病。而每个治疗领域下设人工智能与数字创新、战略、投资组合、运营及沟通团队,形成垂直整合的灵活架构。Marcus ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.